• Describe implications of tumor MGMT promotor methylation status in treatment of glioblastoma
  • Discuss importance of performance status/functional status in assessing people with cancer especially older adults.
  • Apply evidence from randomized clinical trials of older adults with newly diagnosed glioblastoma towards tumor-directed treatment recommendations.
Session date: 
01/12/2026 - 4:00pm to 5:00pm CST
Location: 
In-person and Virtually
1685 Highland Ave
MFCB-Room 1220
United States
See map: Google Maps
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™
Add to calendar: 
Please login or register to take this course.
Discloser List CME Internal Report